{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-013446","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.211401+00:00","generated_at":"2026-05-30T09:18:32.081448+00:00","sec_items":["5.07","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ENDRA Life Sciences stockholders approve reverse stock split; board sets ratio at 1-for-35","bullets":["Stockholders approved reverse stock split at Special Meeting on Oct 28, 2024 with 4,241,540 for, 2,792,189 against, 18,228 abstain.","Board of Directors subsequently approved a ratio of 1-for-35 for the reverse stock split.","Reverse split ratio may be implemented at board's discretion within one year of meeting date; all other proposed ratios abandoned."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-013446","json":"https://secwatch.observer/filing/0001654954-24-013446.json","markdown":"https://secwatch.observer/filing/0001654954-24-013446.md","text":"https://secwatch.observer/filing/0001654954-24-013446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424013446/0001654954-24-013446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424013446/endra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:18:32.081448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}